| Source: |
| Type: |
| Ability to control of muscles |
| 2358- | SK, | SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2 |
| - | in-vivo, | Park, | NA |
| 2138- | TQ, | Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice |
| - | in-vivo, | Nor, | NA |
| 2139- | TQ, | Thymoquinone regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the TLR4 signaling pathway |
| - | in-vivo, | Nor, | NA |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4861- | Uro, | Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions |
| - | in-vivo, | AD, | NA |
| 4874- | Uro, | EGCG, | A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 4334- | VitB5, | Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model |
| - | in-vivo, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1256 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid